http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8829003-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8a2118dc3189383ddbecf50f6af241e7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0381e572cb27c5be24dfb7b01bffe3ea http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_324fdf0805738b536f3f26871b54d0d7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_07ebb005423ffc0920d338e8f718a157 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aad715a1407705313cfbbd14820184e6 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-75 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-47 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-497 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-62 |
| filingDate | 2011-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-09-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_68a66b058a47a44519bfbe6f21242788 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0e51af2d586f57699ddd156faeba58e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2013a6e4d488a7c28a4dbbdac1cd0806 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_457da4894f617156a66d41e6e7a2a425 |
| publicationDate | 2014-09-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-8829003-B2 |
| titleOfInvention | Compounds for treating proliferative disorders |
| abstract | A compound of formula (I) or a pharmaceutically acceptable salt or solvate or physiologically hydrolysable, solubilizing or immobilizable derivative thereof; wherein: any one or two of X., X2 and X3 is a N atom and the remaining two or one of X 1 , X 2 and X 3 are independently CR 13 ; Y is selected from SO 2 and SO; R 1 , R 2 , R 3 , and R 7 and the one or two R 13 groups are each independently selected from H and R 10 , R 10 is selected from R 8 , alkyl, aryl, heteroaryl and combinations of two or more thereof and combinations with one or more R 9 , or R 10 is one or more moieties R 11 Sinking one or more alkyl, alkoxy, aryl, heteroaryl or R 8 or R 9 groups or combinations thereof, directly or via a moiety selected from alkylene, arylene, heteroarylene or combinations thereof, wherein alkyl, aryl, heteroaryl groups or moieties thereof may be substituted with one or more groups R 12 , or R 10 is selected from a group R 12 ; R 11 is selected from 0-, N—, NH—, N═C, CO—, C00-, CON—, CONH—, S0 2 -, S0 2 N—, S0 2 NH—; R 12 is selected from halogen, NH 2 , N0 2 , CN, OH, COOH, CONH 2 , C(═NH)NH 2 , S0 3 H, S0 2 NH 2 , S0 2 CH 3 , OCH 3 , OCH 2 CH 3 , CF 3 ; R 8 and R 9 comprise one or more solubilizing moieties independently chosen from i) neutral hydrophilic groups, ii) ionisable organic acids, iii) ionisable organic bases, iv} chemical functions or moieties providing covalent or non-covalent attachment or binding to a solid phase or an immobile receptor and combinations thereof; R 4 , R 5 and R 6 are each independently selected from H and R 10 , or two of R 4 to R 6 are linked to form a cyclic ether or amine containing one or more additional oxygen or nitrogen atoms. The compound may be used for treating a condition mediated by one or more enzymes selected from AKT, Aurora kinase, BCR-ABL, CDK, FLT, GSK3, IKK, JAK, MAPK, PDGF, PI3K, PKA, PKB, PKC, PLK, Src and VEGF family enzymes, or for treating cancer or other proliferative disorder, or for inhibiting growth of cancer cells, or for inducing apoptosis of cancer cells, in a human or animal subject. |
| priorityDate | 2010-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 947.